L-arginine

Scientists have developed innovative lipid nanoparticles from fenugreek seed oil to enhance the delivery and effectiveness of L-arginine, showing superior antioxidant and anti-inflammatory properties compared to conventional diabetes treatments.

A recent clinical trial investigated the safety and potential benefits of oral L-arginine hydrochloride supplementation in patients with Amyotrophic Lateral Sclerosis (ALS). The study, conducted over 90 days, found that L-arginine was well tolerated with no serious adverse events or deaths related to the intervention. It also suggested a correlation between L-arginine levels and the maintenance of body weight, an important indicator of nutritional status in ALS patients.

A Phase 2 trial of L-arginine in Spinocerebellar Ataxia type 6 (SCA6) showed a trend toward symptom improvement, but the results did not reach statistical significance.